nach oben

International Urology and Nephrology

Erschienen in:

23.08.2017 | Nephrology - Review

Posterior reversible encephalopathy syndrome in children with kidney disease

verfasst von: Cristina Gavrilovici, Ingrith Miron, Luminiţa Voroneanu, Silvia Bădărau, Magdalena Stârcea

Erschienen in: International Urology and Nephrology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Posterior reversible encephalopathy syndrome (PRES) has been described as a neurological condition observed in a variety of clinical settings and is characterized by focal neurological deficits, seizures, headaches, altered mental status, and visual impairment, associated with transient typical lesions on neuroimaging, predominantly in the posterior part of the brain. The most common risk factors for PRES are hypertension, renal diseases, and the use of calcineurin inhibitors. The incidence of PRES in children with renal disorders varies between 4 and 9%, according to different reports. Vasogenic cerebral edema is considered the major pathophysiological mechanism of PRES. There are two main theories regarding the genesis of this edema: (1) hyperperfusion, due to autoregulatory failure of the cerebral vasculature, and (2) hypoperfusion, due to vasoconstriction of the cerebral arteries. In addition, PRES might also be the result of a systemic inflammatory state causing endothelial dysfunction. The management of PRES includes BP control, treatment of seizures, and removal of or reduction in calcineurin inhibitors. Intravenous administration of antihypertensive therapy is preferred, and various drugs have been used in this regard, including nicardipine, labetalol, sodium nitroprusside, and hydralazine. The prognosis of PRES is usually benign, except for rare cases with intracranial hemorrhage.

Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334:494–500CrossRefPubMed

Yamada A, Ueda N (2012) Age and gender may affect posterior reversible encephalopathy syndrome in renal disease. Pediatr Nephrol 27(2):277–283CrossRefPubMed

Ishikura K, Ikeda M, Hamasaki Y, Hataya H, Shishido S, Asanuma H, Nishimura G, Hiramoto R, Honda M (2006) Posterior reversible encephalopathy syndrome in children: its high prevalence and more extensive imaging findings. Am J Kidney Dis 48:231–238CrossRefPubMed

Ishikura K, Hamasaki Y, Sakai T, Hataya H, Mak RH, Honda M (2012) Posterior reversible encephalopathy syndrome in children with kidney diseases. Pediatr Nephrol 27(3):375–384CrossRefPubMed

Onder AM, Lopez R, Teomete U, Francoeur D, Bhatia R, Knowbi O, Hizaji R, Chandar J, Abitbol C, Zilleruelo G (2007) Posterior reversible encephalopathy syndrome in the pediatric renal population. Pediatr Nephrol 22:1921–1929CrossRefPubMed

Ikeda M, Ito S, Hataya H, Honda M, Anbo K (2001) Reversible posterior leukoencephalopathy in a patient with minimal-change nephrotic syndrome. Am J Kidney Dis 37:E30CrossRefPubMed

Stott VL, Hurrell MA, Anderson TJ (2005) Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J 35:83–90CrossRefPubMed

Prasad N, Gulati S, Gupta RK, Kumar R, Sharma K, Sharma RK (2003) Is reversible posterior leukoencephalopathy with severe hypertension completely reversible in all patients? Pediatr Nephrol 18:1161–1166CrossRefPubMed

Casey SO, Sampaio RC, Michel E, Truwit CL (2000) Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 21:1199–1206PubMed

10.

Singh N, Bonham A, Fukui M (2000) Immuno suppressive associated leukoencephalopathy in organ transplant recipients. Transplantation 69:467–472CrossRefPubMed

11.

Schwartz RB (2002) Hyperperfusion encephalopathies: hypertensive encephalopathy and related conditions. Neurologist 8:22–34CrossRefPubMed

12.

Dillon WP, Rowley H (1998) The reversible posterior cerebral edema syndrome. AJNR Am J Neuroradiol 19:591PubMed

13.

Pavlakis SG, Frank Y, Chusid R (1999) Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. J Child Neurol 14:277–281CrossRefPubMed

14.

Chandramohan V, Nagarajan VP, Sathyamoorthi MS et al (2012) Posterior reversible encephalopathy syndrome in a child with autoimmune lymphoproliferative syndrome: case report and review of literature. J Pediatr Neurosci 7(3):221–224CrossRefPubMedPubMedCentral

15.

Arzanian MT, Shamsian BS, Karimzadeh P, Kajiyazdi M, Malek F, Hammoud M (2014) Posterior reversible encephalopathy syndrome in pediatric hematologic-oncologic disease: literature review and case presentation. Iran J Child Neurol 8(2):1–10PubMedPubMedCentral

16.

Gafton B, Porumb V, Ungurianu S, Marinca MV, Cocea C, Croitoru A, Balan G, Miron N, Eliade Ciuleanu T, Miron L (2014) Hepatocellular carcinoma: insights in the biological treatment beyond sorafenib. J BUON 19(4):858–866PubMed

17.

Endo A, Fuchigami T, Hasegawa M, Hashimoto K, Fujita Y, Inamo Y, Mugishima H (2012) Posterior reversible encephalopathy syndrome in childhood: report of four cases and review of the literature. Pediatr Emerg Care 28(2):153–157CrossRefPubMed

18.

El-Naggari MA, Al-Nabhani D, El-Nour I, El-Manzalawy A, Abdelmogheth A-AA (2015) Posterior reversible encephalopathy syndrome in two Omani children with underlying renal diseases. Sult Qaboos Univ Med J 15(3):424–428CrossRef

19.

Saeed B, Abou-Zor N, Amer Z, Kanani I, Hilal M (2008) Cyclosporin-A induced posterior reversible encephalopathy syndrome. Saudi J Kidney Dis Transpl 19(3):439–442PubMed

20.

Gera DN, Patil SB, Iyer A, Kute VB, Gandhi S, Kumar D, Trivedi HL (2014) Posterior reversible encephalopathy syndrome in children with kidney disease. Indian J Nephrol 24(1):28–34CrossRefPubMedPubMedCentral

21.

Tenta M, Uchida HA, Nunoue T, Umebayashi R, Okuyama Y, Kitagawa M, Maeshima Y, Sugiyama H, Wada J (2015) Successful treatment by mycophenolate mofetil in a patient with focal segmental glomerulosclerosis associated with posterior reversible encephalopathy syndrome. CEN Case Rep 4(2):190–195CrossRefPubMed

22.

Sakai N, Kawasaki Y, Imaizumi T, Kanno S, Go H, Mitomo M, Ushijima Y, Suyama K, Ito M, Hashimoto K, Hosoya M (2010) Two patients with focal segmental glomerulosclerosis complicated by cyclosporine-induced reversible posterior leukoencephalopathy syndrome. Clin Nephrol 73:482–486CrossRefPubMed

23.

Nakahara C, Hasegawa N, Izumi I, Kanemoto K, Iwasaki N (2005) The use of cyclosporine in a boy with a prior episode of posterior encephalopathy. Pediatr Nephrol 20:657–661CrossRefPubMed

24.

Soylu A, Kavukcu S, Turkmen M, Akbas Y (2001) Posterior leukoencephalopathy syndrome in poststreptococcal acute glomerulonephritis. Pediatr Nephrol 16:601–603CrossRefPubMed

25.

Ohta T, Sakano T, Shiotsu M, Furue T, Ohtani H, Kinoshita Y, Mizoue T, Kiya K, Tanaka I (2004) Reversible posterior leukoencephalopathy in a patient with Wegener granulomatosis. Pediatr Nephrol 19:442–444CrossRefPubMed

26.

Bartynski WS (2008) Posterior reversible encephalopathy syndrome. I. Fundamental imaging and clinical features. AJNR Am J Neuroradiol 29:1036–1042CrossRefPubMed

27.

Roth C, Ferbert A (2011) The posterior reversible encephalopathy syndrome: What’s certain, what’s new? Pract Neurol 11:136–144CrossRefPubMed

28.

Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA (2010) Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 85:427–432CrossRefPubMedPubMedCentral

29.

McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS et al (2007) Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 189:904–912CrossRefPubMed

30.

Hobson EV, Craven I, Blank SC (2012) Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Peritoneal Dial Int J Int Soc Peritoneal Dial 32(6):590–594CrossRef

31.

Bechstein WO (2000) Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 13:313–326CrossRefPubMed

32.

Bartynski WS (2008) Posterior reversible encephalopathy syndrome. II. Controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 29:1043–1049CrossRefPubMed

33.

De Laat P, te Winkel ML, Devos AS, Catsman-Berrevoets CE, Pieters R, van den Heuvel-Eibrink MM (2011) Posterior reversible encephalopathy syndrome in childhood cancer. Ann Oncol 22:472–478CrossRefPubMed

34.

Magnasco A, Rossi A, Catarsi P, Gusmano R, Ginevri F, Perfumo F, Ghiggeri GM (2008) Cyclosporin and organ specific toxicity: clinical aspects, pharmacogenetics and perspectives. Curr Clin Pharmacol 3:166–173CrossRefPubMed

35.

Mueller-Mang C, Mang T, Pirker A, Klein K, Prchla C, Prayer D (2009) Posterior reversible encephalopathy syndrome: Do predisposing factors make a difference in MRI appearance? Neuroradiology 51:373–383CrossRefPubMed

36.

Jones BV, Egelhoff JC, Patterson RJ (1997) Hypertensive encephalopathy in children. AJNR Am J Neuroradiol 18:101–106PubMed

37.

de Oliveira RA, Fechine LM, Neto FC, Nicodemus JM, Silva GB Jr, Silva LS (2008) Posterior reversible encephalopathy syndrome (PRES) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis. Int Urol Nephrol 40(4):1095–1098CrossRefPubMed

38.

Akutsu N, Iwashita C, Maruyama M, Ootsuki K, Ito T, Saigo K, Kenmochi T (2008) Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients. Transpl Proc 40:2416–2418CrossRef

39.

Ishikura K, Ikeda M, Hamasaki Y, Hataya H, Nishimura G, Hiramoto R, Honda M (2008) Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome. Nephrol Dial Transpl 23(8):2531–2536CrossRef

40.

Mueller AR, Platz KP, Bechstein WO et al (1994) Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 58:155–170CrossRefPubMed

41.

Incecik F, Herguner MO, Altunbasak S, Erbey F, Leblebisatan G (2009) Evaluation of nine children with reversible posterior encephalopathy syndrome. Neurol India 57:475–477CrossRefPubMed

42.

Bai JPF, Lesko LJ, Burckart GJ (2010) Understanding the genetic basis for adverse effects: the calcineurin inhibitors. Pharmacotherapy 30:195–209CrossRefPubMed

43.

Qin W, Tan CY, Huang X, Huang Z, Tao Y, Fu P (2011) Rapamycin-induced posterior reversible encephalopathy in a kidney transplantation patient. Int Urol Nephrol 43(3):913–916CrossRefPubMed

44.

Becquet O, Pasche J, Gatti H, Chenel C, Abely M, Morville P, Pietrement C (2010) Acute post-streptococcal glomerulonephritis in children of French Polynesia: a 3-year retrospective study. Pediatr Nephrol 25:275–280CrossRefPubMed

45.

Gomez-Lado C, Martinon-Torres F, Alvarez-Moreno A, Eiris- Punal J, Carreira-Sande N, Rodriguez-Nunez A, Castro-Gago M (2007) Reversible posterior leukoencephalopathy syndrome: an infrequent complication in the course of haemolytic-uremic syndrome. Rev Neurol 44:475–478PubMed

46.

Punaro M, Abou-Jaoude P, Cimaz R, Ranchin B (2007) Unusual neurologic manifestations (II): posterior reversible encephalopathy syndrome (PRES) in the context of juvenile systemic lupus erythematosus. Lupus 16:576–579CrossRefPubMed

47.

Zhang YX, Liu JR, Ding MP, Huang J, Zhang M, Jansen O, Deuschl G, Eschenfelder CC (2008) Reversible posterior encephalopathy syndrome in systemic lupus erythematosus and lupus nephritis. Intern Med 47:867–875CrossRefPubMed

48.

Ozcakar ZB, Ekim M, Fitoz S, Teber S, Hizel S, Acar B, Yuksel S, Yalcinkaya F (2004) Hypertension induced reversible posterior leukoencephalopathy syndrome: a report of two cases. Eur J Pediatr 163:728–730CrossRefPubMed

49.

Benoist G, Dossier C, Elmaleh M, Dauger S (2013) Posterior reversible encephalopathy syndrome revealing renal artery stenosis in a child. BMJ Case Rep 23:2013

50.

Sharma S, Gupta R, Sehgal R, Aggarwal KC (2014) Atypical presentation of posterior reversible encephalopathy: in a child with bilateral grade IV vesicoureteric reflux. J Trop Pediatr 60:331–333CrossRefPubMed

51.

Girişgen İ, Tosun A, Sönmez F, Özsunar Y (2010) Recurrent and atypical posterior reversible encephalopathy syndrome in a child with peritoneal dialysis. Turk J Pediatr 52:416–419PubMed

52.

Awan AQ, Lewis MA, Postlethwaite RJ, Webb NJA (1999) Seizures following renal transplantation in childhood. Pediatr Nephrol 13:275–277CrossRefPubMed

53.

Zheng W (2001) Neurotoxicology of the brain barrier system: new implications. Clin Toxicol 39:711–719

54.

Tuor UI, Grewal D (1994) Autoregulation of cerebral blood flow: influence of local brain development and postnatal age. Am J Physiol 267:H2220–H2228PubMed

55.

Kwon S, Koo J, Lee S (2001) Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Pediatr Neurol 24:361–364CrossRefPubMed

56.

Lee VH, Wijdicks EF, Manno EM, Rabinstein AA (2008) Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 65:205–210PubMed

57.

Schmithorst VJ, Holland SK, Dardzinski BJ (2008) Developmental differences in white matter architecture between boys and girls. Hum Brain Mapp 29:696–710CrossRefPubMedPubMedCentral

58.

Hughes RL (1990) Cyclosporine-related central nervous system toxicity in cardiac transplantation. N Engl J Med 323:420–421CrossRefPubMed

59.

Schwartz RB, Bravo SM, Klufas RA, Hsu L, Barnes PD, Robson CD, Antin JH (1995) Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol 165:627–631CrossRefPubMed

60.

Ong B, Bergin P, Heffernan T, Stuckey S (2009) Transient seizure-related MRI abnormalities. J Neuroimaging 19:301–310CrossRefPubMed

61.

Peter P, George A (2012) Posterior reversible encephalopathy syndrome and the pediatric population. J Pediatr Neurosci 7(2):136–138CrossRefPubMedPubMedCentral

62.

Covarrubias DJ, Luetmer PH, Campeau NG (2002) Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol 23:1038–1048PubMed

63.

Pande AR, Ando K, Ishikura R, Nagami Y, Takada Y, Wada A, Watanabe Y, Miki Y, Uchino A, Nakao N (2006) Clinicoradiological factors influencing the reversibility of posterior reversible encephalopathy syndrome: a multicenter study. Radiat Med 24:659–668CrossRefPubMed

64.

Ahn KJ, You WJ, Jeong SL, Lee JW, Kim BS, Lee JH et al (2004) Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping. Neuroradiology 46:978–983CrossRefPubMed

65.

Bartynski WS, Boardman JF (2007) Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 28:1320–1327CrossRefPubMed

66.

Servillo G, Bifulco F, De Robertis E, Piazza O, Striano P, Tortora F, Striano S, Tufano R (2007) Posterior reversible encephalopathy syndrome in intensive care medicine. Intensive Care Med 33:230–236CrossRefPubMed

67.

Eichler FS, Wang P, Wityk RJ (2002) Diffuse metabolic abnormalities in reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 23:833–837PubMed

68.

Bartynski WS, Boardman JF (2008) Catheter angiography, MR angiography, and MR perfusion in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 29:447–455CrossRefPubMed

69.

Wright RR, Mathews KD (1996) Hypertensive encephalopathy in childhood. J Child Neurol 11:193–196CrossRefPubMed

70.

Paues J, Vrethem M (2010) Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab. J Clin Virol 48:291–293CrossRefPubMed

71.

Kumar D (2010) Emerging viruses in transplantation. Curr Opin Infect Dis 23:374–378PubMed

72.

Ko MW, Liu GT (2010) Pediatric idiopathic intracranial hypertension (pseudotumor cerebri). Horm Res Paediatr 74:381–389CrossRefPubMed

73.

Lamy C, Oppenheim C, Meder JF, Mas JL (2004) Neuroimaging in posterior reversible encephalopathy syndrome. J Neuroimaging 14:89–96CrossRefPubMed

74.

llner A (2003) In: Blaser SI (ed) Pocket radiologist PedsNeuro. Salt Lake City, UT, medical reference. PRES, New York, pp 220–222

75.

Parvex P, Pinsk M, Bell LE, O’Gorman AM, Patenaude YG, Gupta IR (2001) Reversible encephalopathy associated with tacrolimus in pediatric renal transplants. Pediatr Nephrol 16:537–542CrossRefPubMed

76.

Gavrilovici C, Oprea L (2013) Clinical ethics, research ethics and community ethics-the moral triad of nowadays society. Revista Romana De Bioetica 11(3):3–5

77.

Gavrilovici C, Goldsmith DJ, Reid C, Gubeth-Tatomir P, Covic A (2004) What is the role of ambulatory BP monitoring in pediatric nephrology? J Nephrol 17(5):642–652PubMed

78.

Abe K (2004) Reversible posterior leukoencephalopathy syndrome. Intern Med 43:900–901CrossRefPubMed

79.

Nishida M, Sato H, Kobayashi N, Morimoto M, Hamaoka K (2009) Wernicke’s encephalopathy in a patient with nephrotic syndrome. Eur J Pediatr 168:731–734CrossRefPubMed

Titel: Posterior reversible encephalopathy syndrome in children with kidney disease
verfasst von: Cristina Gavrilovici
Ingrith Miron
Luminiţa Voroneanu
Silvia Bădărau
Magdalena Stârcea
Publikationsdatum: 23.08.2017
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 10/2017
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-017-1684-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Posterior reversible encephalopathy syndrome in children with kidney disease

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2017

Smoking as a risk factor for diabetic nephropathy: a meta-analysis

The impact of fish oil and wheat germ oil combination on mineral-bone and inflammatory markers in maintenance hemodialysis patients: a randomized, double-blind, placebo-controlled clinical trial

Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast

Thymoma-associated renal pathology: Is renal biopsy always necessary? A clinical problem-solving exercise and teaching example for physicians

Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients

Peroxisome proliferator-activated receptor-γ–coactivator 1α (PGC-1α) gene expression in chronic kidney disease patients on hemodialysis: relation to hemodialysis-related cardiovascular morbidity and mortality

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin